Minerva Neurosciences, Inc. (NASDAQ: NERV) screened its first patient in the global Phase 3 confirmatory trial of roluperidone, a monotherapy designed to treat negative symptoms of schizophrenia. The study, designated MIN‑101C19, will enroll roughly 380 adults across about 40 sites worldwide, including the United States and several European countries. It will evaluate a 64 mg dose of roluperidone over 12 weeks, with the primary endpoint being the change from baseline in the PANSS Marder Negative Symptoms Factor Score. A 40‑week extension will compare roluperidone to standard antipsychotics for relapse of positive symptoms.
The trial represents a critical step toward a potential FDA submission and could deliver the first approved treatment for the unmet need of negative schizophrenia symptoms, which affect 50‑60 % of the 2.4 million Americans diagnosed with the disorder. By targeting symptoms that current antipsychotics do not adequately address, roluperidone could transform the therapeutic landscape for a large patient population.
Regulatory context underscores the significance of this milestone. In February 2024, the FDA issued a Complete Response Letter citing insufficient efficacy and safety data for roluperidone, and a prior Phase 3 study in 2020 failed to meet its primary endpoint. The current trial follows FDA guidance on a streamlined Phase 3 approach, aiming to address the deficiencies highlighted in the earlier review and to provide robust data for a potential approval.
Minerva remains a clinical‑stage company with substantial operating losses. In Q4 2023 the company reported a net loss of $9.0 million versus $6.7 million in Q4 2022, and a full‑year 2023 net loss of $30.0 million compared with $32.1 million in 2022. Despite these losses, the company’s liquidity is strong, with a current ratio of 36.28 as of March 2026. To support the Phase 3 trial, Minerva secured a private placement in October 2025 that could provide up to $200 million in funding.
Dr. Remy Luthringer, Executive Chairman and CEO, emphasized the importance of the trial: "Initiation of this confirmatory Phase 3 trial is an important milestone for Minerva and for patients living with persistent and impairing negative symptoms of schizophrenia." He added, "With no approved treatments for this indication in the US, roluperidone remains the only late‑stage candidate in development for this population. The study builds directly on our prior experience showing consistent results across the two earlier trials and our execution strategy gives us confidence in our timelines."
The company expects topline data from the trial in the second half of 2027. If the results demonstrate efficacy and safety, roluperidone could become the first approved therapy for negative schizophrenia symptoms, potentially opening a new therapeutic niche and addressing a critical unmet need for patients worldwide.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.